ÍøºìºÚÁÏ

Skip to main content

Carl J Pepine, MD

Cardiologist (Heart Specialist)

Photo of Carl J Pepine

Research at a glance

Top areas of exploration

  • Coronary Disease , 197 publications
  • Myocardial Ischemia , 186 publications
  • Coronary Artery Disease , 153 publications
  • Hypertension , 141 publications

Research activity

1,073 publications

53,734 citations

Why is this important?

Focus

My career has focused on improving our understanding of mechanisms underlying ischemic heart disease (IHD) and related adverse outcomes. I have conducted extensive investigations in coronary artery disease (CAD), hypertension, treatment resistant hypertension, vascular biology, and therapeutic applications related to vascular dysfunction. My work has centered on how IHD becomes manifest with and without large coronary artery obstructive disease (CAD). Much of this work is concentrated in women with known or suspect IHD. A major goal of clinical research is development of actionable information of sufficient power to alter medical care and improve patient health by information obtained through performance of clinical trials. To this end, I conceived and led the first randomized controlled international mega-trial of blood pressure control for patients with CAD (INVEST). My experience also includes being a principal investigator (PI) in multiple NHLBI-funded projects [Women’s Ischemia Syndrome Evaluation (WISE), WISE-CVD, WISE HFpEF, MayWEST, Asymptomatic Cardiac Ischemia Pilot (ACIP), Psychophysiologic Interventions of Myocardial Ischemia (PIMI), Bypass Angioplasty Revascularization Investigation 2-Diabetes Trial (BARI2D), etc.] and many other industry-sponsored studies. More recently I have been working in cardiovascular recovery and regeneration with cell based therapies as a PI in the NHLBI Cardiovascular Cell Therapy Network (CCTRN)- 1 and 2, as well as studies funded by the the cell and gene biomedical industry.

Active clinical trials

LIBREXIA-ACS

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

Investigator
Carl J Pepine
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
EVOLVE

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic…

Investigator
Carl J Pepine
Status
Accepting Candidates
Ages
18 Years - 99 Years
Sexes
All

My publications

1073 publications

2024

Towards real-time myocardial infarction diagnosis: a convergence of machine learning and ion-exchange membrane technologies leveraging miRNA signatures

Lab on a Chip

•

2023

An international perspective on low-dose aspirin for the primary prevention of myocardial infarction.

International journal of cardiology

•

2023

ANOCA/INOCA/MINOCA: Open artery ischemia

American Heart Journal Plus: Cardiology Research and Practice

•

2023

Association of abnormal electrocardiography response on dobutamine stress echocardiogram with longer-term major adverse cardiovascular events in women with symptoms of ischemic heart disease.

Cardiovascular diagnosis and therapy

•

2023

Association of Coronary Artery Dominance With Long-term Outcomes in Female Patients With Suspected Ischemia but Nonobstructive Coronary Artery Disease.

Journal of the Society for Cardiovascular Angiography & Interventions

•